

No: 22/2026/CV-MP

Hanoi, June 26, 2026

**INFORMATION DISCLOSURE**

**To: - State Securities Commission;**

**- Hanoi Stock Exchange**

1. Company Name: **MEDIPLANTEX NATIONAL PHARMACEUTICAL  
JOINT STOCK COMPANY**

- Stock Code: MED

- Address: No. 358, Giai Phong Road, Phuong Liet Ward, Ha Noi City.

- Person responsible for information disclosure: Mr. Mai Nhat Thanh

**Type of information disclosure:**  Periodic  Extraordinary  As required

2. Information Disclosure Contents:

- Notice of Amendment and Supplement to the Documents of the 2026 Annual General Meeting of Shareholders

3. This information was published on the company's website on June 26, 2026 at the link: <http://www.mediplantex.com/cổ-đông/công-bố-thông-tin>

We hereby commit that the information published above is accurate and are fully legally responsible for the content of the published information./.

**MEDIPLANTEX NATIONAL PHARMACEUTICAL  
JOINT STOCK COMPANY**



**Mai Nhat Thanh**



**AGENDA OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS  
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

**Time: 1:30 PM, Friday, Monday 29, 2026.**

**Venue:** The General Meeting will be held online via electronic voting. Shareholders or authorized representatives can participate in the online General Meeting from any location with an Internet connection. The broadcasting hub for the Chairperson, the Presidium, and the Organizing Committee (the administrative venue) is located at: No. 358 Giai Phong Street, Phuong Liet Ward, Hanoi.

**AGENDA**

<b>Time</b>	<b>Detailed Agenda</b>	<b>Execution</b>
<b>13h00 - 13h30</b>	Instructions for Shareholders on Online Attendance and E-Voting	The Organizing Committee
	Report on Delegate Eligibility Verification	The Delegate Eligibility Committee
<b>13h30 - 14h15</b>	Opening of the meeting and introduction of delegates	The Organizing Committee
	Approval of the Meeting Agenda, Working and Voting-Election Regulations, and the Vote Counting Committee	
<b>14h15 – 15h15 Reports &amp; Proposals</b>	Report of the Board of Directors on its performance in 2025 and the proposed operational plan for 2026.	Representative of the Board of Directors
	Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026.	Representative of the Board of Management
	Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026.	Representative of the Board of Supervisors
	Proposal for the approval of the 2025 audited financial statements;	Representative of the Board of Directors
	Proposal for the selection of an independent auditing firm for the 2026 financial statements;	Representative of the Board of Supervisors
	Proposal for the approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026;	Representative of the Board of Directors
	Proposal for the approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 and the plan for 2026;	Representative of the Board of Directors
	Proposal for the approval of the amendments and supplements to the Charter on Organization and Operation of the Company;	Representative of the Board of Directors
	Approval of the Dismissal of Ms. Nguyen Thi Thuy as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term.	Representative of the Board of Directors
	Approval of the Dismissal of Ms. Tran Nguyen Hoang Phuc as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term	Representative of the Board of Directors
Other matters within the authority of the General Meeting of Shareholders.	Representative of the Board of Directors	
<b>15h15 – 15h30</b>	Discussion of the reports and proposals	Chairperson of the General Meeting
<b>15h30 – 16h00</b>	Conduct voting on the matters submitted to the General Meeting of Shareholders and elect an additional member to the Board of Directors for the 2024–2029 term	
<b>16h00 – 16h15</b>	Announcement of the voting and election results at the General Meeting of Shareholders	Ballot Counting Committee
<b>16h15 – 16h35</b>	Presentation of the draft Minutes and Resolutions of the Meeting	Secretariat
<b>16h35 – 17h00</b>	Approval of the Minutes and Resolutions of the Meeting	Chairperson of the General Meeting
	Conclusion and declaration of the Meeting's closure	



# CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No.: 05/2026/TTtr-DHDCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

Hanoi, June , 2026

DRAFT



## REPORT

*Re.: Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company*

**To: The General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company.

**The Board of Directors respectfully submits the following to the General Meeting of Shareholders for consideration and approval:**

Based on a review of the Company's Charter on Organization and Operation (the "Charter"), the Board of Directors has determined that certain provisions of the Charter should be amended and supplemented to ensure compliance with applicable laws and regulations and to meet practical requirements in the Company's governance and management. (Details of the proposed amendments and supplements are set out in the Appendix attached to this Proposal.)

The full draft of the amended Charter has been published in detail on the Company's website at: <https://www.mediplantex.com/>.

The General Meeting of Shareholders is respectfully requested to authorize the Board of Directors and the Company's Legal Representative to make amendments and supplements to, and to execute and promulgate, the Charter and related documents based on the amendments and supplements approved by the General Meeting of Shareholders.



Furthermore, the General Meeting of Shareholders is respectfully requested to approve in principle and authorize the Board of Directors to carry out the administrative procedures arising from the amendments and supplements to the Charter as follows:

(i) With respect to the amendments to the Company's business lines, head office address, and other contents of the enterprise registration dossier, the Board of Directors and the Legal Representative shall carry out the notification/registration procedures with the Business Registration Authority immediately after such amendments are approved by the General Meeting of Shareholders, within the time limits prescribed by the Law on Enterprises.

(ii) With respect to the change of the Company's Legal Representative, the General Meeting of Shareholders approves in principle such change and authorizes the Board of Directors to determine the effective date thereof, provided that the change shall be completed no later than December 31, 2026. The Board of Directors and the Legal Representative shall complete the registration procedures with the Business Registration Authority in accordance with the Law on Enterprises.

The amended and supplemented Charter on Organization and Operation shall take effect from the date of its approval by the Company's 2026 Annual General Meeting of Shareholders.

*Respectfully submitted to the General Meeting of Shareholders for consideration and approval./.*

**Recipient:**

- Company shareholders;
- Board of Directors, Supervisory Board, Company Secretary;
- Archived at VT, Board of Directors.

**OB. THE BOARD OF DIRECTORS**

**CHAIRMAN**



**Nguyen Ngoc Xuan Trang**

No.: 06/2026/TTr-DHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June , 2026

DRAFT

## PROPOSAL

**Re: Approval of the Dismissal of Ms. Nguyen Thi Thuy as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term**

**To: The General Meeting of Shareholders  
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

- Based on the letter of resignation submitted by the member of the Board of Directors to the Board of Directors;

**The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval of the following matters:**

1. Based on the resignation letter submitted by a member of the Board of Directors, the Board respectfully proposes that the General Meeting of Shareholders approve the dismissal of:

Ms. Nguyen Thi Thuy - Member of the Board of Directors for the 2024–2029 term

Upon the approval of Ms. Nguyen Thi Thuy's resignation, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the 2024–2029 term will consist of only 04 members, thereby failing to meet the structural requirements of the Board of Directors as prescribed by the Company's Charter. Accordingly, the Board of Directors deems it necessary to propose the election of an additional member to the Board of Directors for the 2024–2029 term.

2. The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the election of an additional member of the Board of Directors for the 2024 – 2029 term to replace Ms. Nguyen Thi Thuy, with the following contents:

- Number of additional members to be elected to the BOD: 01 member
- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.
- Number of candidates: Unlimited.

**Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.**

**Recipients:**

- *Company Shareholders;*
- *BOD; BOS;*
- *Archived: Company Secretary.*

**OB. THE BOARD OF DIRECTORS  
CHAIRMAN**

**Nguyen Ngoc Xuan Trang**



No.: 07/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June , 2026

DRAFT

## PROPOSAL

**Re: Approval of the Dismissal of Ms. Tran Nguyen Hoang Phuc as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term**

**To: The General Meeting of Shareholders  
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

- Pursuant to the Resolution of the Board of Directors No. 08/2026/NQ-HĐQT dated May 25, 2026 regarding the supplementation of the agenda of the 2026 Annual General Meeting of Shareholders.

**The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval of the following matters:**

1. The Board of Directors respectfully submits to the General Meeting of Shareholders for approval the dismissal of:

Ms. Tran Nguyen Hoang Phuc - Member of the Board of Directors for the 2024–2029 term

To ensure that the Company's governance and management activities are carried out continuously, stably and effectively, in compliance with applicable laws and the Company's Charter, the Board of Directors considers it necessary to elect an additional member of the Board of Directors for the 2024 – 2029 term.

2. The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the election of an additional member of the Board of Directors for the 2024 – 2029 term to replace Ms. Tran Nguyen Hoang Phuc, with the following contents:

- Number of additional members to be elected to the BOD: 01 member

- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.
- Number of candidates: Unlimited.

**Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.**

**Recipients:**

- *Company Shareholders;*
- *BOD; BOS;*
- *Archived: Company Secretary.*

**OB. THE BOARD OF DIRECTORS  
CHAIRMAN**

**Nguyen Ngoc Xuan Trang**





**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY  
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

**VOTING BALLOT  
DELEGATE ID: .....**

Full name: .....

Number of votes owned:..... votes

Number of votes authorized:..... votes

**Total number of votes represented: .....votes**

*(Check the corresponding box for your choice in each content)*

<b>CONTENT</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
<b>Content 01:</b> Agenda of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 02:</b> Working and Voting Regulations of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 03:</b> The Vote Counting Committee for the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Guide:**

Shareholders tick (X) in one of 3 boxes:

**Approve/Disapprove/Abstain** each Content.

June 29<sup>th</sup> 2026

**DELEGATE**

*(Signature and full name)*



**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY  
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

**VOTING BALLOT  
DELEGATE ID: .....**

Full name: .....

Number of votes owned:..... votes

Number of votes authorized:..... votes

**Total number of votes represented: .....votes**

*(Check the corresponding box for your choice in each content)*

CONTENT	Approve	Disapprove	Abstain
<b>Content 01:</b> Report of the Board of Directors on 2025 performance results and the implementation plan for 2026 activities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 02:</b> Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 03:</b> Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 04:</b> Approval of the 2025 Audited Financial Statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 05:</b> Approval of the Selection of the Independent auditing firm for the 2025 Financial Statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 06:</b> Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 07:</b> Approval of remuneration report for the Board of Directors, Board of Supervisors for 2025 and the plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 08:</b> Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 09:</b> Approval of the Dismissal of Ms. Nguyen Thi Thuy as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 10:</b> Approval of the Dismissal of Ms. Tran Nguyen Hoang Phuc as a Member of the Board of Directors and the Election of an Additional Member of the Board of Directors for the 2024 – 2029 Term.			

**Guide:**

Shareholders tick (X) in one of 3 boxes:

**Approve/Disapprove/Abstain** each Content.

June 29<sup>th</sup> 2026

**DELEGATE**

*(Signature and full name)*



**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY  
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

**VOTING BALLOT  
DELEGATE ID: .....**

Full name: .....

Number of votes owned:..... votes

Number of votes authorized:..... votes

**Total number of votes represented: .....votes**

*(Check the corresponding box for your choice in each content)*

<b>CONTENT</b>	<b>Approve</b>	<b>Disapprove</b>	<b>Abstain</b>
<b>Content 01:</b> Resolution of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Content 02:</b> Meeting Minutes of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Guide:**

Shareholders tick (X) in one of 3 boxes:

**Approve/Disapprove/Abstain** each Content.

June 29<sup>th</sup> 2026

**DELEGATE**

*(Signature and full name)*



**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY  
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS**

**VOTE ON THE BOARD OF DIRECTORS  
DELEGATE ID: .....**

Full name: .....

Number of votes owned:..... votes

Number of votes authorized:..... votes

Total number of votes represented: .....votes

**Total number of voting rights ..... voting rights**

**I hereby agree to cast the votes for the chosen Additional Member of the Board of Directors**

No	Full Name	Cumulative voting	Number of votes
1	...	<input type="checkbox"/>	<input type="text"/>
2	...	<input type="checkbox"/>	<input type="text"/>

**Guide:**

1. The maximum number of candidates that delegates are eligible to elect is equal to the number of candidates needed to elect (02 members)
2. If accumulative elect the entire elect for one or several candidates, delegates mark in “Cumulative voting” of the corresponding candidates.
3. If the number of elections is uneven for many candidates, the delegate must specify the number of elections in the “Number of votes” of the corresponding candidates.

June 29<sup>th</sup>, 2026

**DELEGATE**

*(Signature and full name)*

No.: 01/2026/NQ-DHDCD/MED

Hanoi, June , 2026



## RESOLUTION

### 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

**Pursuant to:**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, as amended by Law No. 56/2024/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its guiding documents;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the Minutes of the 2026 Annual General Meeting of Shareholders No. ... dated June 29, 2026;
- Pursuant to the Vote Counting Minutes of the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company dated June 29, 2026.

The 2026 Annual General Meeting of Shareholders (“AGM” or “GMS”) of Mediplantex National Pharmaceutical Joint Stock Company shall be conducted in the form of an online meeting with electronic voting. The meeting venue for the Chairperson, the Presidium, and the Organizing Committee (the principal venue from which the Meeting is conducted) shall be located at: No. 358 Giai Phong Road, Phuong Liet Ward, Hanoi, Vietnam.

## RESOLUTION

**Article 1.** Approval of the following reports:

- Report of the Board of Directors on the 2025 performance and the proposed operational plan for 2026;
- Report of the Board of Management on the 2025 Business and Production results and the implementation plan for 2026;
- Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026;

Accordingly, the business and production plan for the year 2026 is as follows:



No.	INDICATOR	UNIT	VALUE
I	Total Revenue	Million VND	412,071
II	Cost of Goods Sold	Million VND	321,273
III	Total Gross Profit	Million VND	90,797
IV	Total Selling Expenses	Million VND	4,949
	Financial Expenses	Million VND	5,120
V	Administrative Expenses	Million VND	62,822
VI	Profit Before Tax	Million VND	15,005

**Article 2.** Approval of the 2025 Audited Financial Statements (*Pursuant to Proposal No. 01/2026/TTr-DHĐCĐ dated June 29, 2026*).

**Article 3.** Approval of the Selection of the Independent Auditor for the 2026 Financial Statements (*Pursuant to Proposal No. 02/2026/TTr-DHĐCĐ dated June 29, 2026*).

**Article 4.** Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026 (*Pursuant to Proposal No. 03/2026/TTr-DHĐCĐ dated June 29, 2026*).

**Article 5.** Approval of the remuneration for the Board of Directors and the Board of Supervisors for 2025 (*Pursuant to Proposal No. 04/2026/TTr-DHĐCĐ dated June 29, 2026*).

**Article 6.** Approval of the amendments and supplements to the Charter on Organization and Operation of the Company (*Pursuant to Proposal No. 05/2026/TTr-DHĐCĐ dated June 29, 2026*).

**Article 7.** Approval of the Dismissal for the Additional Members of the Board of Directors for the 2024 – 2029 Term (*Pursuant to Proposal No. 06/2026/TTr-DHĐCĐ and Proposal No. .../2026/TTr-DHĐCĐ dated June 29, 2026*)

- ❖ Dismissal of Ms. Nguyen Thi Thuy and Ms. Tran Nguyen Hoang Phuc from the position of member of the Board of Directors as from the date of approval by the General Meeting of Shareholders.
- ❖ Elect Mr./Ms. ... and Mr./Ms. ... as additional members of the Board of Directors for the 2024–2029 term, effective from the date of approval by the General Meeting of Shareholders.

This Resolution shall take effect from the date of issuance. The Board of Directors, the Board of Supervisors, the Board of Management, and all relevant departments shall be responsible for implementing this Resolution.

**OB. THE 2026 GENERAL MEETING OF SHAREHOLDERS  
CHAIRPERSON**

**Thai Khac Minh**

*Hanoi, June 26 , 2026*

**NOTICE OF NOMINATION, SELF-NOMINATION , AND ELECTION  
FOR SUPPLEMENTARY MEMBER OF THE BOARD OF DIRECTORS  
FOR THE REMAINING 2024 – 2029 TERM**

**Pursuant to:**

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, and its guiding documents, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;*
- *The Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, as amended by Law No. 56/2024/QH15 passed by the National Assembly on November 29, 2024, and its guiding documents;*
- *Decree No. 155/2020/ND-CP dated 31 December 2020 of the Government detailing the implementation of a number of articles of the Law on Securities, as amended and supplemented by No. 245/2025/ND-CP dated 11 September 2025, and its guiding documents;*
- *The Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Company’s Internal Regulation on Corporate Governance, the Operational Regulations of the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company;*

The Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company hereby notifies the esteemed shareholders of the specific regulations regarding the nomination and self-nomination for the election of additional member to the Board of Directors for the remaining 2024 – 2029 term, as follows:

**I. ELECTION ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS  
FOR THE REMAINING 2024 – 2029 TERM**

- Number of additional members of the BOD to be elected (expected): **02 members**.
- Term of the additional member: The remaining duration of the 2024–2029 term.
- Structure of the Board of Directors:

The structure of the Board of Directors must ensure that at least one-third (1/3) of the total number of Board members are non-executive members (i.e., members of the Board of Directors who are not the General Director, Deputy General Directors, Chief Accountant, or other executive managers as defined by the Company’s Charter).



The number of independent member of the Board of Directors must be at least 01 member.

## **II. CRITERIA AND CONDITIONS FOR NOMINATION AND SELF-NOMINATION OF MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2024 - 2029 TERM**

**1. Criteria and Conditions for Member of the Board of Directors:** Members of the Board of Directors shall meet the qualifications and eligibility requirements set out in Article 155 of the 2020 Law on Enterprises, Article 275 of Decree No. 155/2020/ND-CP, Clause 78, Article 1 of Decree No. 245/2025/ND-CP, and Article 10 of the Company's Internal Regulations on Corporate Governance.

**2. Criteria for Independent Members of the Board of Directors:** Independent members of the Board of Directors shall meet the qualifications and eligibility requirements set out in Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulation on Operations of the Board of Directors

**3. Nomination and Candidacy of Candidates for the Board of Directors** (Pursuant to Clause 5, Article 115 of the Law on Enterprises and Article 28 of the Company's Charter)

- a. Shareholders holding ordinary shares shall have the right to aggregate their voting rights for the purpose of nominating candidates to the Board of Directors. Shareholders or groups of shareholders holding 10% or more of the total number of ordinary shares shall have the right to nominate candidates for election to the Board of Directors, as follows:
- A shareholder or group of shareholders holding from 5% to less than 10% of the total voting shares may nominate one (01) candidate;
  - A shareholder or group of shareholders holding from 10% to less than 30% of the total voting shares may nominate up to two (02) candidates;
  - A shareholder or group of shareholders holding from 30% to less than 40% of the total voting shares may nominate up to three (03) candidates;
  - A shareholder or group of shareholders holding from 40% to less than 50% of the total voting shares may nominate up to four (04) candidates;
  - A shareholder or group of shareholders holding from 50% to less than 60% of the total voting shares may nominate up to five (05) candidates;
  - A shareholder or group of shareholders holding from 60% to less than 70% of the total voting shares may nominate up to six (06) candidates;
  - A shareholder or group of shareholders holding from 70% to less than 80% of the total voting shares may nominate up to seven (07) candidates;



- A shareholder or group of shareholders holding from 80% to less than 90% of the total voting shares may nominate up to eight (08) candidates.
- b. Ordinary shareholders forming a group to nominate candidates to the Board of Directors must notify the shareholders attending the General Meeting of Shareholders of such grouping prior to the opening of the General Meeting of Shareholders.
- c. In the event that the number of candidates for the Board of Directors nominated and self-nominated remains insufficient, the incumbent Board of Directors may nominate additional candidates or organize nominations in accordance with a mechanism specified in the Company's internal corporate governance regulations. This nomination mechanism or the procedure for nomination by the incumbent Board of Directors must be clearly disclosed and must be approved by the General Meeting of Shareholders prior to its implementation.

### **III. NOMINATION AND SELF-NOMINATION DOCUMENTS:**

Shareholders or groups of shareholders holding the required percentage as stipulated above, when nominating or applying as candidates for the Board of Directors of the Company, must submit the following documents to the Company either in person or by postal mail:

- Self-Nomination or nomination letter for candidacy to the Board of Directors (using the attached form);
- Information disclosure form (using the attached form);
- Copies of the candidate's legal identification documents;
- Minutes of the shareholders' group meeting (in case a group of shareholders aggregates voting shares to nominate a Board member) (using the attached form);
- Certified copies of relevant academic qualifications (if any) of the candidate/nominee.

### **IV. DEADLINE AND ADDRESS FOR SUBMISSION OF SELF-NOMINATION/ NOMINATION DOCUMENTS**

For the convenience of organizing the election process and preparing election materials, the Company respectfully requests eligible shareholders/shareholder groups wishing to nominate or stand for election to submit by fax or email the nomination/self-nomination dossier as prescribed in Section III above, and concurrently send the original dossier to the Company no later than 9:00 a.m. on 29 June 2026, using the following contact information:

- Contact Address: Mediplantex National Pharmaceutical Joint Stock Company – 358 Giai Phong Street, Thanh Xuan District, Hanoi.
- Contact Person: Ms. Chu Huyen Trang – Position: Company Secretary.
- Tel: 024.38643360 / 0916117939
- Email: trang.chuh@mediplantex.com.



In the event that a shareholder or group of shareholders fails to submit the original copies of the self-nomination/nomination documents as stipulated in Section IV above to the Company prior to the approval of the list of nominees/candidates at the General Meeting, such self-nomination/nomination shall be deemed non-compliant with the provisions of the Law on Enterprises and the Company's Charter, and consequently, the self-nomination/nomination shall be considered invalid at the General Meeting.

Based on the nomination and self-nomination dossiers submitted by shareholders and groups of shareholders, together with the supporting documents of the candidates, the Board of Directors shall compile a list of candidates who satisfy the prescribed eligibility requirements and submit such list to the General Meeting of Shareholders for approval prior to the election of members of the Board of Directors. If, by the date preceding the opening of the General Meeting of Shareholders, the number of nominated and self-nominated candidates for the Board of Directors is less than the number of Board members to be elected, the remaining candidates shall be nominated by the Board of Directors or through a nomination process organized in accordance with applicable laws and the Company's Charter.

**ON BEHALF OF THE BOARD OF DIRECTORS**  
**CHAIR MAN**



**Nguyen Ngoc Xuan Trang**